Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Candel Therapeutics (CADL) Operating Margin (2020 - 2023)

Historic Operating Margin for Candel Therapeutics (CADL) over the last 4 years, with Q4 2023 value amounting to 228.43%.

  • Candel Therapeutics' Operating Margin rose 259038300.0% to 228.43% in Q4 2023 from the same period last year, while for Dec 2023 it was 1479.42%, marking a year-over-year increase of 265213800.0%. This contributed to the annual value of 1596.7% for FY2024, which is 1172800.0% down from last year.
  • Per Candel Therapeutics' latest filing, its Operating Margin stood at 228.43% for Q4 2023, which was up 259038300.0% from 1324.51% recorded in Q3 2023.
  • Candel Therapeutics' Operating Margin's 5-year high stood at 1581.77% during Q1 2023, with a 5-year trough of 28987.1% in Q1 2022.
  • For the 4-year period, Candel Therapeutics' Operating Margin averaged around 15193.5%, with its median value being 17100.0% (2021).
  • Its Operating Margin has fluctuated over the past 5 years, first tumbled by -170322600bps in 2021, then skyrocketed by 305688700bps in 2023.
  • Quarter analysis of 4 years shows Candel Therapeutics' Operating Margin stood at 19758.06% in 2020, then dropped by -26bps to 24967.74% in 2021, then decreased by -5bps to 26132.26% in 2022, then soared by 99bps to 228.43% in 2023.
  • Its Operating Margin was 228.43% in Q4 2023, compared to 1324.51% in Q3 2023 and 1487.42% in Q2 2023.